Interrater reliability of the clinical dementia rating in a multicenter trial

Kenneth Rockwood; David Strang; Chris MacKnight; Robert Downer; John C. Morris

doi:10.1111/j.1532-5415.2000.tb05004.x

Interrater reliability of the clinical dementia rating in a multicenter trial

Kenneth Rockwood, David Strang, Chris MacKnight, Robert Downer, John C. Morris

Research output: Contribution to journal › Article › peer-review

73 Citations (Scopus)

Abstract

OBJECTIVE: To test the interrater reliability of the Clinical Dementia Rating (CDR) in a multicenter clinical trial. DESIGN: Observational study. SETTING: Training session for a multicenter trial of milameline, a direct muscarinic agonist, in the treatment of Alzheimer's disease. PARTICIPANTS: Twenty-four raters (physicians and nurses) familiar with drug trials and expert in the care of patients with Alzheimer's disease. METHODS: Independent scoring of the CDR using four videotaped CDR interviews. OUTCOME MEASURE: Interrater reliability, as tested by the Kappa statistic RESULTS: The overall interrater reliability was 0.62. Within the CDR domains, the global kappas ranged from 0.33 ± 0.06 to 0.88 ± 0.06. CONCLUSIONS: The data support moderate to high overall interrater reliability but show important difficulties in the reliable assessment of early dementia.

Original language	English
Pages (from-to)	558-559
Number of pages	2
Journal	Journal of the American Geriatrics Society
Volume	48
Issue number	5
DOIs	https://doi.org/10.1111/j.1532-5415.2000.tb05004.x
Publication status	Published - May 2000

ASJC Scopus Subject Areas

Geriatrics and Gerontology

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Access to Document

10.1111/j.1532-5415.2000.tb05004.x

Cite this

@article{34a9f329dd2145b28c02e5cc9b34087e,

title = "Interrater reliability of the clinical dementia rating in a multicenter trial",

abstract = "OBJECTIVE: To test the interrater reliability of the Clinical Dementia Rating (CDR) in a multicenter clinical trial. DESIGN: Observational study. SETTING: Training session for a multicenter trial of milameline, a direct muscarinic agonist, in the treatment of Alzheimer's disease. PARTICIPANTS: Twenty-four raters (physicians and nurses) familiar with drug trials and expert in the care of patients with Alzheimer's disease. METHODS: Independent scoring of the CDR using four videotaped CDR interviews. OUTCOME MEASURE: Interrater reliability, as tested by the Kappa statistic RESULTS: The overall interrater reliability was 0.62. Within the CDR domains, the global kappas ranged from 0.33 ± 0.06 to 0.88 ± 0.06. CONCLUSIONS: The data support moderate to high overall interrater reliability but show important difficulties in the reliable assessment of early dementia.",

author = "Kenneth Rockwood and David Strang and Chris MacKnight and Robert Downer and Morris, {John C.}",

year = "2000",

month = may,

doi = "10.1111/j.1532-5415.2000.tb05004.x",

language = "English",

volume = "48",

pages = "558--559",

journal = "Journal of the American Geriatrics Society",

issn = "0002-8614",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - Interrater reliability of the clinical dementia rating in a multicenter trial

AU - Rockwood, Kenneth

AU - Strang, David

AU - MacKnight, Chris

AU - Downer, Robert

AU - Morris, John C.

PY - 2000/5

Y1 - 2000/5

N2 - OBJECTIVE: To test the interrater reliability of the Clinical Dementia Rating (CDR) in a multicenter clinical trial. DESIGN: Observational study. SETTING: Training session for a multicenter trial of milameline, a direct muscarinic agonist, in the treatment of Alzheimer's disease. PARTICIPANTS: Twenty-four raters (physicians and nurses) familiar with drug trials and expert in the care of patients with Alzheimer's disease. METHODS: Independent scoring of the CDR using four videotaped CDR interviews. OUTCOME MEASURE: Interrater reliability, as tested by the Kappa statistic RESULTS: The overall interrater reliability was 0.62. Within the CDR domains, the global kappas ranged from 0.33 ± 0.06 to 0.88 ± 0.06. CONCLUSIONS: The data support moderate to high overall interrater reliability but show important difficulties in the reliable assessment of early dementia.

AB - OBJECTIVE: To test the interrater reliability of the Clinical Dementia Rating (CDR) in a multicenter clinical trial. DESIGN: Observational study. SETTING: Training session for a multicenter trial of milameline, a direct muscarinic agonist, in the treatment of Alzheimer's disease. PARTICIPANTS: Twenty-four raters (physicians and nurses) familiar with drug trials and expert in the care of patients with Alzheimer's disease. METHODS: Independent scoring of the CDR using four videotaped CDR interviews. OUTCOME MEASURE: Interrater reliability, as tested by the Kappa statistic RESULTS: The overall interrater reliability was 0.62. Within the CDR domains, the global kappas ranged from 0.33 ± 0.06 to 0.88 ± 0.06. CONCLUSIONS: The data support moderate to high overall interrater reliability but show important difficulties in the reliable assessment of early dementia.

UR - http://www.scopus.com/inward/record.url?scp=0034063066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034063066&partnerID=8YFLogxK

U2 - 10.1111/j.1532-5415.2000.tb05004.x

DO - 10.1111/j.1532-5415.2000.tb05004.x

M3 - Article

C2 - 10811551

AN - SCOPUS:0034063066

SN - 0002-8614

VL - 48

SP - 558

EP - 559

JO - Journal of the American Geriatrics Society

JF - Journal of the American Geriatrics Society

IS - 5

ER -

Interrater reliability of the clinical dementia rating in a multicenter trial

Abstract

ASJC Scopus Subject Areas

PubMed: MeSH publication types

Access to Document

Other files and links

Fingerprint

Cite this